HeartBeet Clinic
Principal Investigator: Laura Ross, PA-C and Stephanie Hooker, PhD, MPH
Study sponsor: Park Nicollet Foundation
Location: Park Nicollet Heart and Vascular Center
Purpose of study: The goal of the study is to conduct a pilot randomized controlled trial comparing the HeartBeet Clinic, a 16-week lifestyle medicine program with virtual, small-group coaching, to a self-paced, online education program. In this pilot study, the primary goals will be to assess acceptability and feasibility of the study and intervention procedures to prepare for a larger efficacy trial.
Inclusion Criteria:
-Have at least one cardiovascular risk factor, including: a) high cholesterol, as defined as diagnosis of hyperlipidemia and/or most recent total cholesterol > 200 or b) hypertension (as defined by a diagnosis of hypertension and/or active antihypertensive medication prescription) and/or BMI > 27
-Identify as a HealthPartners patient, including having an outpatient encounter with a HealthPartners or Park Nicollet clinician in the prior year
-Be willing to pay for copays/charges for group medical visit and labs drawn as part of usual care if not fully covered by insurance
-Stated willingness to comply with all study procedures and availability for the duration of the study
-Willingness to maintain current doses of statin, anti-obesity medication, and/or antihypertensive medication during the study
-Willingness and ability to attend weekly group coaching sessions for 16 weeks at ≥ 1 scheduled group coaching time
-Access to necessary resources for participating in a technology-based intervention (i.e., computer, smartphone, internet access
Exclusion Criteria:
-Concurrent participation in another treatment or intervention study
-History of coronary artery, cerebrovascular or peripheral arterial disease including myocardial infarction, unstable angina, revascularization, stroke/TIA, carotid intervention, claudication, or congestive heart failure
-Existing diagnosis of dementia and/or other cognitive impairment that would be a barrier to participation
-Individuals who have opted out of being contacted for research
Study Contact:
Stacy Ngwesse
(952) 967-7012
HeartBeetClinicPilot@healthpartners.com
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults (COVID-19 Vaccine Study in Minnesota)
Principal Investigators: Charlene McEvoy, MD, MPH; Zeke McKinney, MD
Study sponsor: AstraZeneca
Location: Bloomington, MN
Phase of Study: Phase III
Purpose of study: The AstraZeneca COVID-19 vaccine study is a clinical research study to evaluate an investigational vaccine for the prevention of COVID-19. In this study, participants will be randomly assigned (by chance) to receive 2 injections of either the investigational vaccine or placebo (4 weeks apart). A placebo looks like the investigational vaccine but contains no active vaccine. There is twice as much chance of receiving the investigational vaccine than of receiving the placebo. Study participation will last about 2 years.
Inclusion Criteria:
-At least 18 years of age
-Are in good or stable health, including having a well-managed underlying medical condition
-Have an increased risk of getting COVID-19, like working in a close-contact profession
-Don’t have a previously confirmed COVID-19 diagnosis
Study Contact:
Visit https://www.healthpartners.com/vaccinestudy for more information about the study and to complete the screening form.
